Evaluation of Erythroferrone, Hepcidin, and Iron Overload Status in Iraqi Transfusion-Dependent β-Thalassemia Major Patients

References

• Muncie JH, Campbell J. α And β thalassemia. Am Fam Physician. 2009;80(4):339–344.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011;152(5):512–523.
   PubMed Web of Science ®Google Scholar
• Rahimi Z. Genetic epidemiology, hematological and clinical features of hemoglobinopathies in Iran. BioMed Res Int. 2013;2013:803487.
   PubMed Web of Science ®Google Scholar
• Al-Hakeim HK, Najm AH, Al-Aldujaili AH, Maes M. Major depression in children with β-thalassemia major is strongly associated with the number of blood transfusions, iron overload and increased levels of interleukin-1β. Neurotox Res. 2020;38(1):228–241.
   PubMedGoogle Scholar
• Choudhry VP. Thalassemia minor and major: current management. Ind J Pediatr. 2017;84(8):607–611.
   PubMed Web of Science ®Google Scholar
• Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol. 2009;16(3):187–194.
   PubMed Web of Science ®Google Scholar
• Abdulzahra MS, Al-Hakeim HK, Ridha MM. Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients. Asian J Transfus Sci. 2011;5(2):127–131.
   PubMedGoogle Scholar
• Hagag AA, Elfrargy MS, Gazar RA, El-Lateef AEA. Therapeutic value of combined therapy with deferasirox and silymarin on iron overload in children with beta thalassemia. Mediterr J Hematol Infect Dis. 2013;5(1).
   PubMedGoogle Scholar
• Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–1443.
   PubMed Web of Science ®Google Scholar
• Coffey R, Ganz T. Iron homeostasis: an anthropocentric perspective. J Biol Chem. 2017;292(31):12727–12734.
   PubMed Web of Science ®Google Scholar
• Zhang DL, Rouault TA. How does hepcidin hinder ferroportin activity? Blood. 2018;131(8):840–842.
   PubMed Web of Science ®Google Scholar
• Aschemeyer S, Qiao B, Stefanova D, et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood. 2018;131(8):899–910.
   PubMed Web of Science ®Google Scholar
• Zhao N, Zhang A-S, Enns CA. Iron regulation by hepcidin. J Clin Invest. 2013;123(6):2337–2343.
   PubMed Web of Science ®Google Scholar
• Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood. 2013;122(1):124–133.
   PubMed Web of Science ®Google Scholar
• Liu J, Sun B, Yin H, Liu S. Hepcidin: a promising therapeutic target for iron disorders: a systematic review. Medicine. 2016;95(14):e3150.
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin and the global burden of iron deficiency. Clin Chem. 2015;61(4):577–578.
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Nemeth E, Ganz T. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014;124(16):2569–2574.
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood. 2015;126(17):2031–2037.
   PubMed Web of Science ®Google Scholar
• Coffey R, Ganz T. Erythroferrone: an erythroid regulator of hepcidin and iron metabolism. Hemasphere. 2018;2(2):e35.
   PubMed Web of Science ®Google Scholar
• Al-Hakeim HK, Alhillawi ZH. Effect of serum fibroblast growth factor receptor 2 and CAPS proteins on calcium status in β-thalassaemia major patients who are free from overt inflammation. Growth Factors. 2018;36(3-4):178–185.
   PubMed Web of Science ®Google Scholar
• Arneson WL, Brickell JM, editors. Hemoglobin production disorders and testing. Clinical Chemistry: A Laboratory Perspective. Philadelphia (PA, USA): FA Davis, 2007. p. 179–200.
   Google Scholar
• Cloonan SM, Mumby S, Adcock IM, et al. The “iron”-y of iron overload and iron deficiency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(9):1103–1112.
   PubMed Web of Science ®Google Scholar
• Wang W, Knovich MA, Coffman LG, et al. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010;1800(8):760–769.
   PubMed Web of Science ®Google Scholar
• Mishra AK, Tiwari A. Iron overload in beta thalassaemia major and intermedia patients. Maedica. 2013;8(4):328–332.
   PubMedGoogle Scholar
• Shah R, Trehan A, Das R, Marwaha RK. Serum ferritin in thalassemia intermedia. Indian J Hematol Blood Transfus. 2014;30(4):281–285.
   PubMed Web of Science ®Google Scholar
• Davis BA, O’Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104(1):263–269.
   PubMed Web of Science ®Google Scholar
• Huang Y, Lei Y, Liu R, et al. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia. Int J Med Sci. 2019;16(2):302–310.
   PubMed Web of Science ®Google Scholar
• Sangkhae V, Nemeth E. Regulation of the iron homeostatic hormone hepcidin. Adv Nutr. 2017;8(1):126–136.
   PubMed Web of Science ®Google Scholar
• Ganz T, Jung G, Naeim A, et al. Immunoassay for human serum erythroferrone. Blood. 2017;130(10):1243–1246.
   PubMed Web of Science ®Google Scholar
• Pasricha SR, Lim PJ, Duarte TL, et al. Hepcidin is regulated by promoter-associated histone acetylation and HDAC3. Nat Commun. 2017;8(1):403–418.
   PubMedGoogle Scholar
• Latour C, Wlodarczyk MF, Jung G, et al. Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia. Haematologica. 2017;102(1):60–68.
   PubMed Web of Science ®Google Scholar
• Camaschella C, Pagani A, Nai A, Silvestri L. The mutual control of iron and erythropoiesis. Int J Lab Hematol. 2016;38(Suppl 1):20–26.
   PubMed Web of Science ®Google Scholar
• Arezes J, Foy N, McHugh K, et al. Erythroferrone inhibits the induction of hepcidin by BMP6. Blood. 2018;132(14):1473–1477.
   PubMed Web of Science ®Google Scholar
• Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014;35(3):155–161.
   PubMed Web of Science ®Google Scholar
• Zivot A, Lipton JM, Narla A, Blanc L. Erythropoiesis: insights into pathophysiology and treatments in 2017. Mol Med. 2018;24(1):11–26.
   PubMedGoogle Scholar
• Ramos P, Melchiori L, Gardenghi S, et al. Iron metabolism and ineffective erythropoiesis in β-thalassemia mouse models. Ann NY Acad Sci. 2010;1202:24–30.
   PubMed Web of Science ®Google Scholar
• Haghpanah S, Esmaeilzadeh M, Honar N, et al. Relationship between serum hepcidin and ferritin levels in patients with thalassemia major and intermedia in Southern Iran. Iran Red Crescent Med J. 2015;17(7):e2834.
   Web of Science ®Google Scholar
• Metz CE. ROC methodology in radiologic imaging. Invest Radiol. 1986;21(9):720–733.
   PubMed Web of Science ®Google Scholar